Groundbreaking new research has found synthetic cannabidiol can kill bacteria associated with gonorrhoea, meningitis and legionnaires disease.
The research, published in a peer-reviewed journal article in Communications Biology on Wednesday, explores antimicrobial activity of CBD and the potential to advance CBD analogs as a “much-needed new class of antibiotics”.
It found the psychoactive component of cannabis could kill a subset of gram-negative bacteria including neisseria gonorrhoeal, which causes gonorrhoea, Australia’s second most common sexually-transmitted disease.
Click through to read the full article on The Australian here.
https://botanixpharma.com/wp-content/uploads/Screen-Shot-2021-01-20-at-4.06.42-pm.png6881222Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2021-01-20 05:10:522023-03-13 21:16:45CBD oil kills gonorrhoea bacteria, potential for ‘much-needed new class of antibiotics’
Queensland researchers are studying a component of medicinal cannabis for its potential as a new antibiotic, capable of killing superbugs.
The big hope for scientists at the University of Queensland’s Institute for Molecular Bioscience is that synthetic cannabidiol, or CBD, the main non-psychoactive component of cannabis, could be developed into the first new class of antibiotics for drug-resistant bacteria in more than half a century.
The quest for new antibiotics is seen as crucial by infectious disease experts, with predictions that by 2050, drug-resistant infections could result in 10 million deaths a year unless alternate treatments are found.
Click through to read the full article on The Courier Mail here.
https://botanixpharma.com/wp-content/uploads/Screen-Shot-2021-01-20-at-11.43.21-am.png7961402Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2021-01-20 00:44:362023-03-13 21:16:45Qld researchers on how cannabis could be used to fight superbug
“This is the first time CBD has been shown to kill some types of Gram-negative bacteria. These bacteria have an extra outer membrane, an additional line of defence that makes it harder for antibiotics to penetrate,” Dr Blaskovich said.
In Australia, gonorrhoea is the second most common sexually-transmitted infection and there is no longer a single reliable antibiotic to treat it because the bacteria is particularly good at developing resistance.
The study also showed that CBD was widely effective against a much larger number of Gram-positive bacteria than previously known, including antibiotic-resistant pathogens such as MRSA (methicillin-resistant Staphylococcus aureus) or ‘golden staph’.
Dr Blaskovich said cannabidiol was particularly good at breaking down biofilms—the slimy build-up of bacteria, such as dental plaque on the surface of teeth—which help bacteria such as MRSA survive antibiotic treatments.
Dr Blaskovich’s team at the Centre for Superbug Solutions mimicked a two-week patient treatment in laboratory models to see how fast the bacteria mutated to try to outwit CBD’s killing power.
“Cannabidiol showed a low tendency to cause resistance in bacteria even when we sped up potential development by increasing concentrations of the antibiotic during ‘treatment’.”
“We think that cannabidiol kills bacteria by bursting their outer cell membranes, but we don’t know yet exactly how it does that, and need to do further research.
The research team also discovered that chemical analogs – created by slightly changing CBD’s molecular structure—were also active against the bacteria.
“This is particularly exciting because there have been no new molecular classes of antibiotics for Gram-negative infections discovered and approved since the 1960s, and we can now consider designing new analogs of CBD within improved properties.”
Vince Ippolito, the President and Executive Chairman of Botanix, said the research showed vast potential for the development of effective treatments to fight the growing global threat of antibiotic resistance.
“Congratulations to Dr Blaskovich and his team for producing this significant body of research—the published data clearly establishes the potential of synthetic cannabinoids as antimicrobials,” Mr Ippolito said.
“Our Company is now primed to commercialise viable antimicrobial treatments which we hope will reach more patients in the near future. This is a major breakthrough that the world needs now.”
Dr Blaskovich said collaborating with Botanix has sped up the research, with Botanix contributing formulation expertise that has led to the discovery that how cannabidiol is delivered makes a huge difference in its effectiveness at killing bacteria.
The collaboration has enabled Botanix to progress a topical CBD formulation into clinical trials for decolonisation of MRSA before surgery.
“Those Phase 2a clinical results are expected early this year and we hope that this will pave the way forward for treatments for gonorrhoea, meningitis and legionnaires disease.
“Now we have established that cannabidiol is effective against these Gram-negative bacteria, we are looking at its mode of action, improving its activity and finding other similar molecules to open up the way for a new class of antibiotics.”
This research has been published in Communications Biology. See journal article HERE.
Video news release and b-roll package is available HERE.
https://botanixpharma.com/wp-content/uploads/UQ-Photo-scaled.jpg19202560Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2021-01-19 22:18:022023-03-13 21:16:45UQ media release | Research establishes antibiotic potential for cannabis molecule
https://botanixpharma.com/wp-content/uploads/Screen-Shot-2020-11-20-at-8.13.00-am.png11341412Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2020-11-19 21:13:592023-03-13 21:16:45Superbugs will kill 22,000 Australians annually by 2040; but these stocks are trying to stop that
“Is this just a projection…?” The narrator of this video asks, as she examines the possibility of a world devoid of effective antibiotics, a most precious resource.Due to “use, misuse, overuse” of antibiotics, a dire future is forecast. It is thought provoking, unnerving – but also deeply motivating to be part of global action to address antimicrobial resistance (AMR).Here at Botanix, we are committed to developing novel solutions to address AMR through our BTX 1801 pipeline. In World Antimicrobial Awareness Week (#WAAW) it’s encouraging to see this vital conversation gaining momentum too. Watch the video on Financial Timeshere.
https://botanixpharma.com/wp-content/uploads/Screen-Shot-2020-11-20-at-7.42.10-am.png6421054Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2020-11-18 21:02:002023-03-13 21:16:45Antibiotic resistance: a matter of time
https://botanixpharma.com/wp-content/uploads/Screen-Shot-2020-11-18-at-2.59.11-pm.png5761102Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2020-11-17 03:59:002023-03-13 21:16:45Botanix Pharmaceuticals updates on meeting with FDA
The Australian Government Department of Health has this week published a summary of funding and strategy measures announced to address antimicrobial resistance (AMR) in the recent 2020-21 Federal Budget. This includes $22.5m to address the priorities identified in Australia’s National Antimicrobial Resistance Strategy – 2020 & Beyond.
Key areas, as quoted in this excerpt, include:
Surveillance ofAntimicrobial Use and Resistance
Continuation and enhancement of the Antimicrobial Use and Resistance (AURA) Surveillance System that provides a comprehensive and integrated picture of trends of antimicrobial use and resistance in human health.
Assessment of Australia’s current capabilities and resource needs to develop a One Health Surveillance System. This scoping and planning phase will entail consultation with stakeholders on how to achieve the implementation of a One Health Surveillance System that integrates resistance and usage data from human health, animal health, agriculture, food and environment sectors in Australia.
The Department of Agriculture, Water and the Environment will conduct scoping studies to collect baseline data on antimicrobial resistance and usage in the animal health sector.
A pilot study will be conducted to collect baseline data on the presence of antimicrobials and resistant organisms in food. FSANZ will be responsible for this project which will commence in mid-2021.
Support for the development of a Multi-Drug Resistant Organism (MRO) outbreak response capability with state and territory health authorities. This will enable a timely response to outbreaks of priority MROs detected by surveillance; building on existing capacity.
Develop a National AMR One Health Research and Development Agenda (AMR R&D Agenda). The intention is to work with stakeholders to identify gaps and priority areas for research on the prevention, detection and containment of AMR across the differing areas of research; i.e. operational and implementation, therapeutics, preventives and diagnostics. The agenda will also consider opportunities for collaboration, both nationally and internationally, and to reduce potential duplication of effort.
Undertake a scoping study on pricing and reimbursement to identify new and innovative funding models to support incentivising new products that prevent, detect and contain drug-resistant infections in Australia. The study will be informed by the outcomes and lessons learned of similar studies conducted internationally.
Develop a national monitoring and evaluation framework to measure Australia’s progress towards achieving the objectives of the 2020 AMR Strategy. This work is planned to commence in mid-2021.
Maintain Australia’s AMR governance arrangements such as the Australian Government’s AMR advisory group; the Australian Government One Health AMR website (amr.gov.au), and meeting national and international reporting obligations.
Botanix Pharmaceuticals’ President and Executive Chairman, Vince Ippolito, commented: “Botanix Pharmaceuticals has this week announced that we have secured a clear development path from the FDA for our BTX 1801 synthetic cannabidiol antimicrobial product, following the successful completion of a Pre-Investigational New Drug (Pre-IND) meeting. Our BTX 1801 Phase 2a study in Perth is fully enrolled and remains on track for completion before the end of this calendar year.
“We welcome support from the Australian Federal Government as we develop our BTX 1801 antimicrobial pipeline and are committed to active and collaborative participation in the whole-of-industry response needed to address this pressing global health emergency.”
– ENDS –
https://botanixpharma.com/wp-content/uploads/AdobeStock_126570978-scaled.jpeg17072560Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2020-11-13 04:50:332023-03-13 21:16:45Australian Government makes strong commitment to fund the fight against AMR
Botanix (ASX:BOT) has today announced it has secured a clear development path from the FDA for its BTX 1801 synthetic cannabidiol antimicrobial product, following the successful completion of a Pre-Investigational New Drug (Pre-IND) meeting.
Our team will have more clinical data to share soon too – our BTX 1801 Phase 2a study in Perth is fully enrolled and remains on track for completion before the end of this calendar year.
https://botanixpharma.com/wp-content/uploads/WEBSITE.png9001600administrator/wp-content/uploads/botanix-logo.pngadministrator2020-10-12 21:28:002023-03-13 21:17:07Antimicrobial resistance: a global health emergency